Condition
Giant Cell Tumor of Tendon Sheath
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 3 (2)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT05804045Phase 3Active Not Recruiting
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05059262Phase 3Active Not Recruiting
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT03069469Phase 1Active Not Recruiting
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Showing all 3 trials